Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ORIC with free AI briefings, catalyst countdowns, and dilution alerts.

ORIC · ORIC Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$345.4M Cash on Hand
28.2mo Cash Runway
10.5% Short Interest
$21.79 Analyst Target (14)
Follow ORIC by email Get an email when ORIC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ORIC, unsubscribe in one click. Privacy

📣 What ORIC Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Rinzimetostat (ORIC-944) Metastatic Castration Resistant Prostate Cancer Phase 3 · NCT07723248 Recruiting
Enozertinib (ORIC-114) Solid Tumors Phase 1/2 · NCT05315700 Recruiting
Nab-paclitaxel Solid Tumor Phase 1 · NCT03928314 Terminated
CD73 Inhibitor ORIC-533 Relapsed or Refractory Multiple Myeloma Phase 1 · NCT05227144 Completed
Glucocorticoid Receptor Antagonist ORIC-101 Solid Tumor Phase 1 · NCT03928314 Terminated

Also used in these trials (approved or third-party drugs, not ORIC's own candidates): Darolutamide, Docetaxel Anhydrous, Enzalutamide, Carboplatin, Amivantamab, Abiraterone Acetate, Apalutamide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ORIC holds $345.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $36.8M/quarter from operations, an estimated runway of 28.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 15 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ORIC files for a raise →

👥 Who Owns ORIC

Insiders 1% Institutions (257 holders) 99% Public and other holders 0%
HolderTypeShares% of sharesAs of
Nextech Invest, Ltd. Institution (13F) 7,162,637 6.89% 2026-09-30
VIKING GLOBAL INVESTORS LP Institution (13G, 5%+) 6,002,989 5.78% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 5,473,145 5.27% 2025-12-31
Price (T.Rowe) Associates Inc Institution (13F) 5,088,495 4.90% 2026-09-30
Aihc Capital Management Ltd Institution (13F) 4,630,986 4.46% 2026-09-30
SR One Capital Management, LP Institution (13F) 4,615,384 4.44% 2026-09-30
State Street Corporation Institution (13F) 4,126,317 3.97% 2026-09-30
NEA Management Company, LLC Institution (13F) 4,118,621 3.96% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 4,072,661 3.92% 2026-09-30
Column Group LLC Institution (13F) 3,540,777 3.41% 2026-09-30
Jacob Chacko
PRESIDENT AND CEO, Director · +1.39M options
Insider 581,711 0.56% 2025-12-15
Richard A. Heyman
Director · +153,953 options
Insider 241,772 0.23% 2026-10-01

Share count 103,931,597 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-20
filed 2026-10-21
Piscitelli Dominic
Option exercise (M) 14,000 $4.36 83,828
2026-10-20
filed 2026-10-21
Piscitelli Dominic
Sale (S) 14,000 $13.53 69,828
2026-10-20
filed 2026-10-21
Piscitelli Dominic
Option exercise (M) 14,000 – –
2026-10-01
filed 2026-10-02
Heyman Richard A.
Option exercise (M) 3,500 $1.60 41,800
2026-10-01
filed 2026-10-02
Heyman Richard A.
Sale (S) 3,500 $12.91 38,300

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ORIC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ORIC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.